Expanding Global Partnerships Through Participation in BIO USA

Lotte Biologics announced on June 4 that it will participate in the 2026 BIO International Convention (also known as BIO USA), which will be held this month in San Diego, United States.


BIO USA is the world's largest pharmaceutical and biotechnology industry exhibition, hosted annually by the Biotechnology Innovation Organization (BIO) in the United States. It attracts a diverse range of participants, including pharmaceutical companies, investment institutions, and research organizations from around the globe, seeking business collaboration opportunities. Lotte Biologics has participated in the event for five consecutive years, from 2022 through this year.

Aerial View of Lotte Biologics Booth at Bio International 2026. Lotte Biologics

Aerial View of Lotte Biologics Booth at Bio International 2026. Lotte Biologics

View original image

This year, the Lotte Biologics booth will feature a lounge for visitor interactions and private meeting rooms designed for discussions with global clients. Additionally, the company will host an "In-booth Presentation" to showcase its vision and business competencies, and organize an interactive event focused on ADC (antibody-drug conjugate), which is a key production modality.


The In-booth Presentation will be held three times throughout the event. On the first day, Lotte Biologics and Asimov will deliver a joint presentation introducing their collaborative strategies in development and production. On the second day, the company will share its scaling up strategies to enhance efficiency during production expansion, utilizing Computational Fluid Dynamics (CFD) technology to analyze fluid flow within bioreactors. On the third day, the presentation will focus on the digitalization of manufacturing processes, presenting directions for digital transformation and operational innovation to showcase its smart manufacturing capabilities.


Notably, this year's booth will feature photos and video content revealing the actual appearance of the Songdo Bio Campus Plant 1. With the plant scheduled for completion in August, the company will introduce its production processes, floor-by-floor layout, and core facilities, highlighting its large-scale commercial manufacturing capabilities and customized production competitiveness. Based on this, the company plans to concretely demonstrate not only the full-scale opening of the Songdo era but also the operational advantages of its dual-site system connecting North America and Asia.



A Lotte Biologics representative stated, "With the completion of Songdo Bio Campus Plant 1 approaching, we are now able to showcase our competitive manufacturing capabilities to potential global clients," adding, "We will further strengthen our global CDMO competitiveness based on our dual-site operational system connecting Syracuse and Songdo."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing